1 / 15

GTP Scenario # 1

GTP Scenario # 1. September 17,2005. Scenario # 1. J Smith is 10 months old with leukemia in remission. He is scheduled to receive a PBPC transplant from HLA matched, ABO major incompatible sibling . Product has excessive RBCs and CD34 + cells. Lab is to:

vittorio
Download Presentation

GTP Scenario # 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. GTP Scenario # 1 September 17,2005

  2. Scenario # 1 • J Smith is 10 months old with leukemia in remission. He is scheduled to receive a PBPC transplant from HLA matched, ABO major incompatible sibling. • Product has excessive RBCs and CD34+ cells. • Lab is to: • Perform a density gradient separation in 50 ml conical tubes. • Freeze ‘excess’ cells.

  3. Laboratory Information • Cell Therapy Laboratory: • Unclassified facility. • BSC cleaned with an appropriate cleaning agent before use (1 product per BSC). • BSC is certified annually. • Centrifuge cleaned as part of preventive maintenance (not before use). • What level of EM and Cleaning is required?

  4. What should be considered? • Evaluate the conditions. • The process is ‘open’. • The product is a 361 GTP product. • The laboratory is an unclassified room. • Cell manipulations occur in the BSC.

  5. Product Monitoring • Sterility: Pre & Post processing? • Recommended • Periodic audit review of sterility results? • Recommended

  6. BSC Environmental Monitoring • Settle plates during processing? • Recommend performing as part of process validation. Review data and determine need based on risk assessment. • Surface sampling after cleaning? • Perform as part of validation and as periodic check of cleaning procedure. • Airborne sampling during processing? • Only perform if settle plate data inconclusive or trending upward.

  7. Facility Monitoring • Perform air particle counts during processing? • Recommend periodic checks during laboratory ‘working hours’ (dynamic monitoring).

  8. Centrifuge Monitoring • Perform EM sampling of the surfaces (buckets)? • Recommend performing as part of process validation. • Recommend performing after preventive maintenance. • Recommend performing during processing only if products begin to have positive sterility results.

  9. Personnel Monitoring • Perform on day of processing after the staff completes the process? • Recommend performing as part of process validation and/or employee training. • Recommend performing during processing only if products begin to have positive sterility results.

  10. EM & PM Result Review • How often? • Recommend monthly review. • Does this need to be done before product release? • Review cannot be part of product release; the product is infused immediately after processing (fresh).

  11. Cleaning • BSC? • Centrifuge? • Lab benchtops? • Lab floors? • Control rate freezer? • Document Review?

  12. Cleaning Recommendations • BSC: Clean before & after use with an appropriate cleaning agent. • Unless validation EM/PM results indicate this is not adequate. • Unless post-processing cultures become positive (investigation outcome). • Unless there is a spill.

  13. Cleaning Recommendations • Centrifuge & Benchtops: • Clean before & after use with appropriate cleaning agent. • Control Rate Freezer: • Clean on a periodic basis as per manufacturer’s instructions. • Floors: • Clean on a periodic basis. • Unless validation EM/PM results indicate this is not adequate. • Unless post-processing cultures become positive (investigation outcome). • Unless there is a spill.

  14. Cleaning Document Review • How often? • Recommend periodic document review. • Does this need to be done before product release? • Review should not be part of product release.

  15. Variation • Would you do anything differently if the donor were HCV positive? • Consider whether cleaning agent in use is viricidal

More Related